This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

RADTOX: Measuring Radiation Toxicity Using Circulating DNA (RADTOX)

This study is currently recruiting participants.
See Contacts and Locations
Verified June 2017 by University of Florida
Sponsor:
Collaborators:
DiaCarta Inc.
National Institutes of Health (NIH)
Information provided by (Responsible Party):
University of Florida
ClinicalTrials.gov Identifier:
NCT02941029
First received: October 13, 2016
Last updated: June 5, 2017
Last verified: June 2017
  Purpose
This research study is being done to develop a new test to identify prostate cancer patients at highest risk of radiotherapy-related complications. This research study would allow monitoring of total tissue damage within 24 hours of radiation exposure in blood samples that could give an initial result within a few days that would help clinicians make treatment decisions. Detection of unusual tissue damage at this early time, well before symptoms occur, could allow doctors to tailor interventions that could include patient therapies that would reduce or prevent the problems that occur due to treatment of their cancer.

Condition Intervention
Prostate Cancer Other: Plasma Blood collection

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: RADTOX: Measuring Radiation Toxicity Using Circulating DNA

Resource links provided by NLM:


Further study details as provided by University of Florida:

Primary Outcome Measures:
  • Free circulating DNA will be measured in patients undergoing radiation for prostate cancer as a toxicity biomarker compared to CTCAE v4.0 [ Time Frame: 9 Months ]

Secondary Outcome Measures:
  • Free circulating DNA will be measured in patients undergoing radiation for prostate cancer as a toxicity biomarker compared pain scores [ Time Frame: 9 Months ]
  • Free circulating DNA will be measured in patients undergoing radiation for prostate cancer as a toxicity biomarker compared and visual analog scales of toxicity [ Time Frame: 9 Months ]

Biospecimen Retention:   Samples With DNA
collection of plasma

Estimated Enrollment: 70
Actual Study Start Date: October 2016
Estimated Study Completion Date: April 2018
Primary Completion Date: March 2017 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Evaluate toxicity biomarkers
Investigators will determine if measurement of circulating DNA from tumor and normal tissues shortly after RT provides an early and quantitative measure of risk of radiation-related complications. It will be necessary to collect blood specimens prior to and during the first week of radiation therapy.
Other: Plasma Blood collection
Plasma blood collection is collected at specific intervals prior to and during radiation treatment.
Other Name: Plasma/Blood Collection

Detailed Description:

Currently, a patient's risk for toxicity is based almost exclusively on population statistics. Radiation (and chemotherapy) dose are based on phase I data and not on the individual's specific genetics or hidden predispositions. RadTox measures cell damage within 24 hours of radiation exposure and should help identify patients at higher risk for radiation complications. This should allow physicians to adjust radiation field size and dose to minimize long-term toxicity.

Patients undergoing radiation treatment for stage I to III prostate cancer, using protons or X-rays, either as primary treatment or consolidation after prostatectomy (positive margins or prostate-specific assay [PSA]-related indications) will be eligible. Hormone treatment will be allowed.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Male patients with undergoing radiation therapy for prostate cancer
Criteria

Inclusion Criteria:

  • Consent to participate in the study and a signed and dated an institutional review board (IRB)-approved consent form conforming to federal and institutional guidelines.
  • ≥ 18 years of age.
  • Patients must have an Eastern Cooperative Oncology Group (An ECOG) performance status of 0 or 1.
  • A diagnosis of adenocarcinoma of the prostate.
  • Not yet begun definitive therapy with chemotherapy or radiation but may have hormones or surgery.
  • Clinically stage I to III tumors.

Exclusion Criteria:

  • Metastatic disease.
  • A history of invasive rectal malignancy or other pelvic malignancy, regardless of disease-free interval.
  • Active inflammatory bowel disease (i.e., patients requiring current medical interventions or who are symptomatic).
  • Prior pelvic radiation therapy for any reason.
  • Psychiatric or addictive disorders or other conditions that, in the opinion of the principal investigator (PI), would preclude the patient from meeting the study requirements.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02941029

Contacts
Contact: John Lybarger, MPH, CCRC 352-265-0680 ext 87829 LYBARJ@shands.ufl.edu
Contact: Andrew Chadwick, MPH, CCRP 352-265-0680 ext 87820 chadwa@shands.ufl.edu

Locations
United States, Florida
University of Florida Health Recruiting
Gainesville, Florida, United States, 32610
Contact: John M Lybarger, MPH    352-265-0680 ext 87829    lybarj@shands.ufl.edu   
Contact: Andrew Chadwick    352-265-0680 ext 87820    chadwa@shands.ufl.edu   
Principal Investigator: Randall Henderson, MD         
University of Florida Health Proton Therapy Institute Recruiting
Jacksonville, Florida, United States, 32206
Contact: David Monticalvo, MPH    904-588-1512    dmonticalvo@floridaproton.org   
Sponsors and Collaborators
University of Florida
DiaCarta Inc.
National Institutes of Health (NIH)
Investigators
Principal Investigator: Randal Henderson, MD, MBA Clinical Professor
  More Information

Responsible Party: University of Florida
ClinicalTrials.gov Identifier: NCT02941029     History of Changes
Other Study ID Numbers: IRB201601961
261201600063C-0-0-1 ( US NIH Grant/Contract Award Number )
Study First Received: October 13, 2016
Last Updated: June 5, 2017
Individual Participant Data  
Plan to Share IPD: No
Plan Description: Data will be shared with necessary government agencies, the sponsor, and participating providers and institutions as defined in the informed consent document.

Keywords provided by University of Florida:
Radiation
Chemotherapy

ClinicalTrials.gov processed this record on June 22, 2017